LOS ANGELES--(BUSINESS WIRE)--July 8, 2007 - Cougar Biotechnology,
Inc. (OTCBB:CGRB) today announced that positive Phase I and Phase
II data on the Company's prostate cancer drug candidate CB7630
(abiraterone acetate) were presented at the European Society for
Medical Oncology (ESMO) Conference, which is currently taking place
in Lugano, Switzerland. The data were presented in two oral and
poster presentations on Sunday, July 8, as part of the session for
genitourinary (prostate) cancer that took place. The poster
presentations are further detailed below:

The Phase I/II trial of CB7630 was conducted at The Institute of
Cancer Research and at The Royal Marsden NHS Foundation Trust in
the United Kingdom. In the trial, CB7630 was administered orally,
once daily, to chemotherapy-naive patients with castration
resistant prostate cancer (CRPC), who had progressive disease
despite treatment with LHRH analogues and multiple other hormonal
therapies. To date, a total of 47 patients have been treated in the
Phase I/II trial, including 15 patients treated in the Phase I
portion of the trial and 32 patients treated in the Phase II
portion of the trial. Of the 38 patients who were evaluable, all of
the patients had radiological evidence of metastatic disease.
Moreover, all of the patients had previously failed treatment with
LHRH analogs and antiandrogens, while 20 patients (53%) had failed
treatment with diethylstilboestrol and 19 patients (50%) had failed
treatment with steroids.

In her poster and oral presentation, Dr. Alison Reid from The
Institute of Cancer Research and The Royal Marsden NHS Foundation
Trust in the United Kingdom reported that CB7630 was well tolerated
at doses as high as 2000 mg/day with minimal toxicity. Moreover, no
dose limiting toxicity has been observed in the trial to date.

In the 38 patients who were evaluable in the Phase I/II trial,
33 patients (87%) experienced a decline in prostate specific
antigen (PSA) levels with 23 patients (61%) experiencing a
confirmed decline in PSA levels of greater than 50%, and with 10 of
the 38 patients (26%) experiencing PSA declines of greater than
90%. Of the 20 evaluable patients with measurable tumor lesions,
treatment with CB7630 resulted in partial radiological responses
(as measured by the RECIST criteria) in 11 patients (55%), with 7
patients demonstrating ongoing stable disease and 3 patients
experienced regressing bone disease. Individual patients treated
with CB7630 also experienced improvement in pain and a reduction in
opioid use.

Currently 21 of the 38 patients (55%) in the Phase I/II trial
remain on study and are continuing to be treated with CB7630. For
the 38 evaluable patients in the trial, the median time to PSA
progression has not been reached and is currently estimated to be
252 days (8.4 months).

The Phase II trial of CB7630 in patients with advanced prostate
cancer who have failed docetaxel-based chemotherapy is being
conducted at numerous locations in the United States and United
Kingdom. In the trial, CB7630 is administered orally, once daily,
to patients with castration resistant prostate cancer who have
failed treatment with androgen deprivation therapy and failed
treatment with first line docetaxel-based chemotherapy. To date, a
total of 43 patients have been enrolled in the trial.

In his poster and oral presentation, Dr. Gerhardt Attard from
The Institute of Cancer Research and The Royal Marsden NHS
Foundation Trust in the United Kingdom provided an update on the 30
patients in this Phase II trial who have been treated in the United
Kingdom. Of these 30 patients, all of the patients had failed
treatment wi
th LHRH analogs and antiandrogens, 21 patients (70%)
had failed treatment with steroids and 15 patients (50%) had failed
treatment with diethylstilboestrol. Moreover, all of the patients
in the study had failed treatment with docetaxel and 10 patients
(33%) had failed treatment with an additional cytotoxic agent
(mitoxantrone, estramustine, vinorelbine, cyclophosphamide).

Of the 30 patients who have been treated, CB7630 was well
tolerated with only minimal toxicity in this post-docetaxel
population. In the 21 patients who have been in the study for over
3 months, 10 patients (48%) experienced a confirmed decline in PSA
levels of greater than 50% and 2 patients (10%) experienced PSA
declines of greater than 90%. Of the 12 evaluable patients with
measurable tumor lesions, 2 patients (17%) experienced confirmed
partial radiological responses (as measured by the RECIST
criteria), 1 patient (8%) experienced an unconfirmed partial
response and 5 patients experienced ongoing stable disease
(including one patient with a minor response). Individual patients
treated with CB7630 also experienced improvement in pain and a
reduction in opioid use. Twenty-eight of the 43 patients (65%)
enrolled in this trial are still receiving treatment with
CB7630.

Dr. Arie S. Belldegrun, M.D., FACS, Vice Chairman of the Board
of Directors of Cougar Biotechnology, said, "The data on CB7630
presented at the ESMO Conference is important for several reasons.
First, not only does it confirm the earlier signal of clinical
activity in second line hormonal therapy patients, but it also for
the first time demonstrates that CB7630 is capable of impacting
time to progression in patients with metastatic disease. The time
to progression data presented in the CB7630 trial compares
favorably to that which has been reported for other currently used
second line hormonal therapies. Second, the data provides
additional confirmation of CB7630's activity in second line
chemotherapy patients. As both
addressable patient populations,
including second line hormone therapy candidates and second line
chemotherapy candidates, continue to represent significant unmet
medical needs in CRPC, we believe that CB7630 has strong potential
in both of these patient populations." Alan H. Auerbach, Chief
Executive Officer and President of Cougar Biotechnology, added, "We
are pleased to be able to present data from both of these CB7630
trials at ESMO. We look forward to continuing to provide updates on
these ongoing trials at future cancer conferences and greatly look
forward to the continued development of CB7630 in both the second
line hormone therapy and second line chemotherapy settings."

About Cougar Biotechnology

Cougar Biotechnology, Inc. is a Los Angeles-based biotechnology
company established to in-license and develop clinical stage drugs,
with a specific focus on the field of oncology. Cougar's oncology
portfolio includes CB7630, a targeted inhibitor of the 17-alpha
hydroxylase/c17,20 lyase enzyme, which is currently being tested in
Phase II clinical trials in prostate cancer; CB3304, an inhibitor
of microtubule dynamics, which is currently in a Phase I trial in
hematological malignancies and CB1089, an analog of vitamin D,
which has been clinically tested in a number of solid tumor
types.

Further information about Cougar Biotechnology can be found at
www.cougarbiotechnology.com.

This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements are often, but not always, made through the
use of words or phrases such as ``anticipates,'' ``expects,''
``plans,'' ``believes,'' ``intends,'' and similar words or phrases.
These forward-looking statements include, without limitation,
statements related to benefits to be derived from Cougar's drug
development programs, including the potential advantages of CB7630
and its potential for use in the treatment of CRPC and in
second
line hormone and chemotherapy treatment settings. Such statements
involve risks and uncertainties that could cause Cougar's actual
results to differ materially from the anticipated results and
expectations expressed in these forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties.
Actual events or results may differ materially from those projected
in any of such statements due to various factors, including the
risks and uncertainties inherent in clinical trials, and drug
development and commercialization, including the uncertainty of
whether results in testing of CB7630 will be predictive of results
in later stages of development. For a discussion of these and other
factors, please refer to Cougar's annual report on Form 10-KSB for
the year ended December 31, 2006 as well as other subsequent
filings with the Securities and Exchange Commission. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. This caution is
made under the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. All forward-looking statements are
qualified in their entirety by this cautionary statement and Cougar
undertakes no obligation to revise or update this press release to
reflect events or circumstances after the date hereof.

(Date:9/12/2017)... FRANCISCO , Sept. 12, 2017 ValGenesis ... Management Solutions (VLMS), is pleased to announce the ... a member of its Board of Directors and ... ValGenesis VLMS enables life science companies to manage ... the use of paper in this process. Furthermore, ...

(Date:10/13/2017)... ... 2017 , ... While it’s often important to take certain medications during the ... Texas, has identified a solution. , She developed a prototype for MOTION LIGHT-UP PILL ... it eliminates the need to turn on a light when taking medication during the ...

(Date:10/13/2017)... ... October 13, 2017 , ... ... certification process to promote standards of excellence for the field of eating disorders, ... March 22 – 25, 2018 in Orlando, Florida at the Omni Resort at ...

(Date:10/13/2017)... ... ... Apple Rehab Shelton Lakes , which specializes in the delivery of ... part of a disaster drill on October 3rd. , Apple Rehab participated with the ... as well as the Connecticut Long Term Care Mutual Aid Plan (LTC-MAP). The ...